ImpediMed Limited (IPDQF)

OTCMKTS · Delayed Price · Currency is USD
0.0140
-0.0030 (-17.65%)
At close: Feb 10, 2026
Market Cap21.06M -60.8%
Revenue (ttm)9.49M +23.3%
Net Income-16.26M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,000
Average Volume52,952
Open0.0140
Previous Close0.0170
Day's Range0.0140 - 0.0140
52-Week Range0.0099 - 0.0514
Beta1.31
RSI44.01
Earnings DateApr 24, 2026

About ImpediMed

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fl... [Read more]

Sector Healthcare
Founded 1999
Employees 77
Stock Exchange OTCMKTS
Ticker Symbol IPDQF

Financial Performance

In fiscal year 2025, ImpediMed's revenue was 12.72 million, an increase of 23.31% compared to the previous year's 10.32 million. Losses were -23.24 million, 17.4% more than in 2024.

Financial numbers in AUD Financial Statements

News

ImpediMed Limited (IPDQF) Q2 2026 Earnings Call Transcript

ImpediMed Limited (IPDQF) Q2 2026 Earnings Call Transcript

2 months ago - Seeking Alpha

ImpediMed Limited (IPDQF) Q1 2026 Earnings Call Transcript

ImpediMed Limited (OTCPK:IPDQF) Q1 2026 Earnings Call October 29, 2025 6:00 PM EDT Company Participants Parmjot Bains - MD, CEO & Director Scott Long - Senior Vice President of US Sales, Key Accounts,...

5 months ago - Seeking Alpha